Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 186497-07-4, Zd4054, Zibotentan (zd4054), Zd-4054, 2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-n-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide

Molecular Formula

C₁₉H₁₆N₆O₄S

Molecular Weight

424.4 g/mol

InChI Key

FJHHZXWJVIEFGJ-UHFFFAOYSA-N

FDA UNII

8054MM4902

Zibotentan is an orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.

1 2D Structure

Zibotentan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide

2.1.2 InChI

InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)

2.1.3 InChI Key

FJHHZXWJVIEFGJ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4

2.2 Other Identifiers

2.2.1 UNII

8054MM4902

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic Acid

2. Zd4054

2.3.2 Depositor-Supplied Synonyms

1. 186497-07-4

2. Zd4054

3. Zibotentan (zd4054)

4. Zd-4054

5. 2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-n-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide

6. N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide

7. Zd 4054

8. Zibotentan (zd4054 )

9. N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide

10. 8054mm4902

11. C19h16n6o4s

12. Zibotentan [usan:inn:jan]

13. Unii-8054mm4902

14. Zibotentanzd4054

15. Zibotentan,zd4054

16. Zibotentan [mi]

17. Zibotentan [inn]

18. Zibotentan [jan]

19. Zibotentan [usan]

20. Zibotentan [mart.]

21. Zd4054 Form 1

22. Zibotentan [who-dd]

23. Mls006011121

24. Schembl847090

25. Zibotentan (jan/usan/inn)

26. Gtpl3539

27. Chembl1628688

28. Zibotentan, >=98% (hplc)

29. Chebi:94573

30. Dtxsid70870171

31. Hms3654h10

32. Bcp02389

33. Bdbm50532593

34. Mfcd09955343

35. S1456

36. Akos015909372

37. Ccg-264894

38. Cs-0492

39. Db06629

40. Sb17118

41. Ncgc00242479-01

42. Ncgc00242479-02

43. Ncgc00242479-03

44. Ncgc00242479-05

45. Ac-32741

46. As-57168

47. Hy-10088

48. Smr004702902

49. Ft-0768122

50. Ns00068495

51. Sw219504-1

52. D07741

53. H11009

54. L001670

55. Q198371

56. Brd-k31553034-001-01-4

57. 3-pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-

58. 3-pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-

59. N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)pridine-3-sulfonamide

60. N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2- Yl)phenyl]pyridine-3-sulfonamide

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₆N₆O₄S
Molecular Weight	424.4 g/mol
XLogP3	1.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	6
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	141
Heavy Atom Count	30
Formal Charge	0
Complexity	654
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in prostate cancer.

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find Zibotentan manufacturers, exporters & distributors on PharmaCompass

Zibotentan

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?